Literature DB >> 15680394

Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.

Raja S Mahidhara1, Pierre E Queiroz De Oliveira, Jaromir Kohout, David G Beer, Jiayuh Lin, Simon C Watkins, Paul D Robbins, Steven J Hughes.   

Abstract

BACKGROUND: Decreased cell-surface expression of Fas (CD95) results in resistance to Fas-mediated apoptosis in esophageal adenocarcinoma (EA). Because p53 is known to increase transcription of Fas and also may induce trafficking of the protein to the plasma membrane, we investigated whether the loss of wild-type (wt)-p53 function accounts for our previous findings.
MATERIALS AND METHODS: Surgical specimens of Barrett's Esophagus containing areas of dysplasia were immunostained for p53 and Fas protein expression. Three EA cell lines were transfected with a wt-p53 containing adenovirus to examine the effects of p53 overexpression. The p53 status of these EA cell lines was determined by sequence analysis.
RESULTS: Regions of dysplasia where p53 protein accumulation was observed corresponded to areas of loss of Fas expression. Sequence analysis of the p53 coding sequence in three EA cell lines (Seg-1, Bic-1, and Flo-1) that retain Fas protein within the cytoplasm, demonstrated that Seg-1 contained wt-p53, but mutations were found in Flo-1 and Bic-1 cell lines. Adenoviral transduction of the cell lines with wt-p53 resulted in cell growth arrest in Seg-1 and Bic-1 and induced cell death in Flo-1, but did not result in an increase in Fas protein expression, cell-surface expression, or restoration of sensitivity to Fas-mediated apoptosis.
CONCLUSIONS: These data suggest that decreased cell-surface expression of Fas and resistance to Fas-mediated apoptosis may occur independently of loss of wt p53 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15680394     DOI: 10.1016/j.jss.2004.08.016

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the beta-catenin-E-cadherin axis.

Authors:  Suman Kambhampati; Snigdha Banerjee; Kakali Dhar; Smita Mehta; Inamul Haque; Gopal Dhar; Monami Majumder; Gibanananda Ray; Peter J Vanveldhuizen; Sushanta K Banerjee
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

3.  Norsolorinic acid from Aspergillus nidulans inhibits the proliferation of human breast adenocarcinoma MCF-7 cells via Fas-mediated pathway.

Authors:  Clay C C Wang; Yi-Ming Chiang; Po-Lin Kuo; Jiunn-Kae Chang; Ya-Ling Hsu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-03-16       Impact factor: 4.080

4.  Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma.

Authors:  Gregory A Watson; Pierre E Queiroz de Oliveira; Michael T Stang; Michaele J Armstrong; William E Gooding; Shih-Fan Kuan; John H Yim; Steven J Hughes
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

5.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

6.  MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway.

Authors:  Ya-Fei Zhang; An-Ran Zhang; Bi-Cheng Zhang; Zhi-Guo Rao; Jian-Fei Gao; Mu-Han Lv; Yu-Yun Wu; Su-Min Wang; Rong-Quan Wang; Dian-Chun Fang
Journal:  Mol Biol Rep       Date:  2012-10-30       Impact factor: 2.316

Review 7.  Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

8.  Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma.

Authors:  Steven L Due; David I Watson; Isabell Bastian; Ann-Kathrin Eichelmann; Damian J Hussey
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.